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Abstract
Background: The major histocompatibility complex class I (MHC-I) molecule is a protein complex that displays
intracellular peptides to T cells, allowing the immune system to recognize and destroy infected or cancerous cells.
MHC-I is composed of a highly polymorphic HLA-encoded alpha chain that binds the peptide and a Beta-2-
microglobulin (B2M) protein that acts as a stabilizing scaffold. HLA mutations have been implicated as a mechanism
of immune evasion during tumorigenesis, and B2M is considered a tumor suppressor gene. However, the implications
of somatic HLA and B2M mutations have not been fully explored in the context of antigen presentation via the MHC-I
molecule during tumor development. To understand the effect that B2M and HLA MHC-I molecule mutations have on
mutagenesis, we analyzed the accumulation of mutations in patients from The Cancer Genome Atlas according to
their MHC-I molecule mutation status.
Results: Somatic B2M and HLA mutations in microsatellite stable tumors were associated with higher overall mutation
burden and a larger fraction of HLA-binding neoantigens when compared to B2M and HLA wild type tumors. B2M and
HLA mutations were highly enriched in patients with microsatellite instability. B2M mutations tended to occur relatively
early during patients’ respective tumor development, whereas HLA mutations were either early or late events. In
addition, B2M and HLA mutated patients had higher levels of immune infiltration by natural killer and CD8+ T
cells and higher levels of cytotoxicity.
Conclusions: Our findings add to a growing body of evidence that somatic B2M and HLA mutations are a mechanism
of immune evasion by demonstrating that such mutations are associated with a higher load of neoantigens that
should be presented via MHC-I.
Introduction
Immune evasion is one of the hallmark traits character-
istic of cancer cells [1]. The near universal requirement
for tumor cells to evade immune elimination implicates
the immune system as a major selective force acting on
developing tumors. When a tumor cell successfully
evades the immune system, the mutations harbored
within can persist and propagate as the cell divides.
In humans, the HLA-A, HLA-B, and HLA-C genes en-
code major histocompatibility complex class I (MHC-I)
molecules, which display intracellular peptides on the
cell surface for inspection by CD8+ T cells. These T cells
have the potential to recognize the MHC-I-peptide com-
plex and become activated cytotoxic T cells (CTLs).
Cancer immunotherapies that target CTL activation rely
on clinical selection of appropriate neoantigens, mutated
peptides specific to tumor cells, to stimulate a response
[2]. Although these cancer immunotherapies are of high
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interest to patients and clinicians, they have not yet
shown widespread clinical success [3].
The MHC-I molecule is composed of a highly poly-
morphic HLA encoded alpha chain and a beta-2-
microglobulin (B2M) protein that acts as a stabilizing
scaffold. B2M is essential for MHC-I complex formation
and peptide presentation. B2M mutations and loss of
heterozygosity (LOH) are linked to decreased MHC class
I expression and decreased patient survival [4, 5]. In
addition to HLA-A, HLA-B, and HLA-C, B2M binds to
other immune proteins including CD1, FCGRT, HFE,
HLA-E, HLA-G LILRB, and MR1. Somatic mutations in
HLA-A and HLA-B have also been shown to be under
positive selection during tumorigenesis and are more
frequent when tumor immune cell infiltration and cyto-
toxicity are high [6]. Importantly, MHC-I molecule pres-
ence on the cell surface can provide an inhibitory signal
to natural killer (NK) cell mediated effector functions
[7]. In addition to classical HLA molecules HLA-A,
HLA-B, HLA-C, and HLA-G, nonclassical HLA-E acts
as a ligand to inhibitory receptors on NK cells. Thus,
both presence and antigen presentation function of
MHC-I molecules contribute to anti-tumor immunity.
A recent study found that an individual’s HLA geno-
type can facilitate immune evasion and shape the land-
scape of a patient’s acquired mutations [8]. Somatic
mutations generating peptides with low affinity for an
individual’s respective HLA alleles were likely to evade
immune detection and persist in the tumor. Somatic
LOH in the human leukocyte antigen (HLA) locus is
thought to impair immune surveillance and was re-
ported to occur in 40% of non-small-cell lung cancers.
The authors found that HLA LOH was significantly as-
sociated with a high mutational burden and cancer-
specific neoantigens generated from these mutations
were biased to bind to the lost HLA allele [9]. Thus, im-
mune evasion may depend on an individual’s unique
HLA genotype and the specificity of neoantigens for par-
ticular HLA alleles.
We previously observed an uncharacteristic enrich-
ment of somatic mutations at B2M interaction partner
binding interfaces [10]. Whereas for most cancer genes,
mutations occurred preferentially on the cancer gene it-
self, genes encoding B2M binding partners showed al-
most as many somatic mutations as B2M (Fig. 1a).
Given B2M’s role as a central component of MHC-I, we
hypothesized that mutations affecting B2M’s interaction
with HLA-A, HLA-B, and HLA-C could facilitate
immune evasion by altering the availability of MHC-I
molecules with distinct specificities, thus affecting
presentation of specific peptides to the immune system
(Fig. 1b). To gain a better understanding of the role of
somatic mutations affecting B2M and its partners in im-
mune evasion, we examined their effect on mutation
burden, antigen binding affinity, immune infiltration,
and cytotoxicity in tumors sequenced by The Cancer
Genome Atlas (TCGA).
Results
HLA and B2M mutations in TCGA
B2M mutation calls were obtained directly from the
MAF files provided by TCGA. Because the HLA locus is
highly polymorphic, mutation calls against the reference
genome are unreliable. Instead, we ran Polysolver [6] to
simultaneously call patient-specific HLA types and de-
tect somatic mutations affecting a patient’s HLA alleles.
Out of 10,428 TCGA patients that had the necessary
whole exome sequencing data, only 579 patients had an
HLA mutation and 125 patients had B2M mutations.
Most of these mutations were nonsynonymous (Fig. 2a).
To determine whether nonsynonymous mutations oc-
curred at amino acid residues with the potential to
interfere with formation of the MHC-I molecule, ex-
perimental 3D structures for the B2M-HLA complex
were obtained from the Protein Data Bank [11] and
used to annotate amino acid residue location at pro-
tein core, surface or at the physical interface between
B2M and HLA encoded proteins (Methods).
Mutations on HLA proteins, particularly HLA-A,
showed a biased distribution with several recurrent hot-
spots (Fig. 2b). Mutations were most concentrated in the
α3 domain that mediates interaction with the T cell re-
ceptor (TCR) (206 mutations, 40.63% of total; OR = 2.04,
p < 2.58e-09), and included multiple recurrent hotspots.
Fifty-one mutations (10.06%) were observed in the trans-
membrane domain including additional hotspots. Al-
though mutations were observed throughout the α1 and
α2 domains that form the peptide binding groove, they
tended to be less recurrent (88 mutations, 17.36% for
both α1 and α2). This may reflect the much larger het-
erogeneity of this region across HLA alleles.
Recurrent hotspot mutations often targeted interface
and core regions on HLA-A, while they targeted core
and surface regions on HLA-B, and surface regions on
HLA-C (Fig. 2b). Since there are many alleles for each
HLA protein, we used the consensus of residue annota-
tions across different alleles to annotate each HLA pro-
tein (Additional file 1: Figure S1). Even though the
annotations for most frequently mutated residues were
in agreement between different HLA alleles, there were
some exceptions, including residue 231 on HLA-A. Al-
though residue 231 (R231) on HLA-A was annotated as
surface based on the consensus across HLA-A alleles,
the residue is located very close to the interface region
(Fig. 2b) and in fact was predicted as an interface residue
on 2 of the 6 HLA-A allele structures analyzed. Add-
itionally, although residue 209 (R209) on HLA-A and
HLA-B proteins was annotated as ambiguous due to its
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intermediate value of relative solvent accessible surface
area (RSA) for most HLA-A/B structures analyzed, the
average RSA across structures is close to the threshold
for core annotation (7.17), and R209 was indeed anno-
tated as core in some of them. Overall, the distribution
of HLA mutations for the three proteins was consistent
with the previous report by Shukla et al. [6], though the
current analysis incorporates an overall larger number of
samples. Mutations in B2M were largely loss of function
(Fig. 2a) and more broadly distributed (Fig. 2c), as ex-
pected for a tumor suppressor gene, though several posi-
tions were also recurrently mutated.
Expected effects of B2M versus HLA mutations on MHC-I
composition
Since B2M is an essential component of all MHC-I mol-
ecules, loss of B2M should equally impact MHC-I mole-
cules derived from different HLA alleles. The B2M
interface with HLA alleles is shared across the different
alleles (Additional file 2: Figure S2), so mutations at this
interface are also likely to affect all variants of an indi-
vidual’s MHC-I molecule, although complexes involving
B2M and binding partners that use alternative interfaces
should not be affected. In contrast, loss of function or
interface mutations affecting a specific HLA allele would
only affect the MHC-I molecules derived from that al-
lele. Thus, we speculate that B2M mutations are likely to
reduce the total amount of MHC-I molecules presenting
antigens on the tumor cell surface, while HLA mutations
would impact which mutations could be presented as
neoantigens.
Mutations in MHC-I proteins are associated with increased
mutation burden
We hypothesized that both B2M and HLA mutations
would affect MHC-I presentation of mutations. Mice
with total lack of B2M express little if any cell surface
MHC-I and lack cytotoxic CD8+ T Cells [12, 13]. In hu-
man lung cancers, an association was found between
higher somatic mutation burden and HLA loss of het-
erozygosity [9]. If somatic mutations to HLA and B2M
similarly impair antigen presentation, we would expect
to see an increased mutation burden when comparing to
unmutated patients.
We first analyzed 9055 TCGA patients across 31 solid
tumor types that had both exome and RNA sequencing
data (Fig. 3a), removing patients that had synonymous
B2M or HLA mutations. We then performed a cancer-
specific analysis of 3514 patients across 8 solid tumor
types with at least 5 somatic B2M and HLA mutations
(Fig. 3b, Additional file 3: Figure S3A). To determine
whether somatic mutations to B2M and HLA were asso-
ciated with an overall higher mutation burden, we com-
pared the total number of expressed nonsynonymous
mutations in patients with and without nonsynonymous
somatic B2M or HLA mutations. Overall, we observed
A B
Fig. 1 Somatic mutations affecting components of the MHC-I molecule. a The total number of nonsynonymous mutations targeting the genes
encoding the components of the MHC-I complex, B2M and HLA-A, HLA-B or HLA-C proteins, across all TCGA patients. The HLA mutation counts
were obtained via Polysolver. b Schematic representation of the effects of mutations that alter the cell surface composition of MHC-I. An HLA
mutation will affect a specific MHC-I molecule, whereas a B2M mutation will affect all MHC-I molecules; both mutations can increase the mutation
burden of the patient. In the case of an HLA mutation, the patient mutation burden should include more neoantigens with affinity for the mutated
HLA allele. The MHC-I molecule displayed is composed of B2M (pink) and HLA-A (blue) proteins (PDB: 3bo8)
Castro et al. BMC Medical Genomics 2019, 12(Suppl 6):107 Page 3 of 13
AC
B
Fig. 2 (See legend on next page.)
Castro et al. BMC Medical Genomics 2019, 12(Suppl 6):107 Page 4 of 13
(See figure on previous page.)
Fig. 2 Mutational analysis of MHC-I complex. a Pie charts displaying percentages of types of mutation for the B2M protein; and for the combined
HLA-A, HLA-B and HLA-C proteins, respectively, across all TCGA patients. b Distribution of nonsynonymous mutation counts, obtained from
Polysolver, for HLA-A, HLA-B, and HLA-C proteins, across functional domains. The corresponding functional domains of HLA proteins are
shown at the bottom. The UniProt sequential residue numbering scheme is used for residue numbering, which requires subtraction of
the signal peptide (24 residues) for mapping to the IMGT/HLA residue numbering scheme. On the right, 3D crystal structures of MHC-I
complex are displayed as B2M and HLA-A complex (PDB: 3bo8), as B2M and HLA-B complex (PDB: 3b3i), and as B2M and HLA-C complex
(PDB: 4 nt6). Purple ribbons indicate B2M protein, while blue ribbons indicate the HLA proteins. The highlighted purple and blue residues
correspond to the interface regions of B2M and HLA proteins, respectively. Hotspot mutations for HLA proteins (frequency > 3 for HLA-A,
frequency > 3 for HLA-B, and frequency > 1 for HLA-C) are highlighted as green, red, tan and gray indicating interface, core, surface, and
ambiguous residues, respectively. c Distribution of nonsynonymous mutation counts across the entire B2M protein. On the bottom of the
plot, all amino acid residues of B2M protein are colored based on their 3D location: interface, core, surface, or ambiguous
A B
C D
Fig. 3 Increased mutational burden is related to mutations in MHC-I. a and c Boxplots showing the total number of expressed nonsynonymous
mutations of TCGA patients who acquired a mutation in their B2M protein or in one of their HLA alleles versus patients who did not acquire any
B2M or HLA mutation, (a) for all patients, and (c) for only MSS patients. Sample sizes for each patient group are written under their name. b and
d Boxplots showing total number of expressed nonsynonymous mutations for TCGA patients with or without B2M or HLA mutations, (b) for all
patients, and (d) for only MSS patients. Patients are divided by tumor type and only the tumor types with at least 5 mutated patients are shown.
P-values are adjusted for multiple comparisons using the Benjamini–Hochberg procedure. Sample sizes for each patient group are written under
the tissue name
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that both patients with a B2M and an HLA mutation
had significantly higher tumor mutation burdens (Mann
Whitney test, B2M p < 1.1e-20 and HLA p < 1.1e-30)
than patients without (Fig. 3a). Pan-cancer, B2M mu-
tated patients also had significantly higher mutation bur-
dens than HLA mutated patients (Mann Whitney test,
p < 0.0028). There were approximately equal numbers of
early stage (I & II) and late stage (III & IV) tumors in
these three groups (Additional file 4: Figure S4). We re-
peated the pan-cancer mutational burden analysis with
Cancer Cell Line Encyclopedia (CCLE) data for 25 B2M-
mutated cell lines, 114 HLA cell lines, and 1381 non-
mutated cell lines, and observed the same trend: cell
lines with B2M and HLA mutations had significantly
higher overall mutational burden than cell lines without
(Additional file 5: Figure S5). When we analyzed tumors
by tissue type, we observed that certain cancers (stom-
ach adenocarcinoma, endometrial cancer, colorectal can-
cer, lung adenocarcinoma, and cervical cancer) also had
significantly higher mutational burden in mutated pa-
tients (Fig. 3b). Stomach, uterine and colorectal cancers
have documented high rates of microsatellite instability
(MSI), thus we evaluated whether B2M and HLA muta-
tions were biased to occur in high MSI tumors. Using
MSI annotations available for 10,415 patients from
Kautto et al. [14], we found a significant bias for B2M
and HLA mutations to occur in patients with MSI
(Fisher’s exact test; B2M OR = 14.66, p < 8.7e-24; HLA
OR = 6.28, p < 2.0e-36). To rule out the possibility that
MSI was solely driving our results, we reanalyzed the
mutational burden between B2M and HLA mutated and
unmutated patients, this time retaining only 8668 micro-
satellite stable (MSS) patients. Interestingly, we found
similar trends in elevated mutational burden associated
with B2M and HLA mutation (Fig. 3c, d, Additional file 3:
Figure S3B), and consequently focused on MSS patients
only in the subsequent analyses. Thus, even in MSS tu-
mors, B2M and HLA mutations are associated with an in-
creased nonsynonymous mutational burden.
Mutations in MHC-I proteins are associated with increased
binding neoantigen counts
To obtain more evidence as to whether the elevated mu-
tation counts observed in HLA and B2M mutated pa-
tients were a result of the mutation, or vice versa, we
compared the fraction of mutations likely to generate
neoantigens across MSS patients with and without B2M
and HLA mutations. We speculated that if B2M and
HLA mutations are an artifact of higher mutation rates,
the proportion of mutations that generate neoantigens
should not differ relative to patients without such muta-
tions. However, if these mutations truly facilitate im-
mune escape, neoantigens should be enriched among
the observed mutations.
Using HLA allele genotypes called by Polysolver [6],
we calculated patient-specific MHC-I presentation
scores for all expressed mutations observed in each pa-
tient’s tumor [8, 15]. We previously demonstrated that
these affinity-based presentation scores, called PHBR-I
scores, can distinguish peptides found in complex with
MHC-I on the cell surface in mass spectrometry experi-
ments from random peptides simulated from the human
proteome, supporting that affinity is a reasonable proxy
for cell surface presentation [8]. Indeed, when we looked
at the fraction of expressed mutations considered to be
neoantigens at various PHBR-I cutoffs, we found that at
any given cutoff, a higher fraction of mutations repre-
sented neoantigens in both B2M and HLA mutated pa-
tients (Figs. 4a, b). This corresponded to overall higher
numbers of neoantigens in B2M and HLA mutant tu-
mors (Additional file 6: Figure S6). The higher overall
proportion of neoantigens is consistent with both som-
atic B2M and HLA mutations impairing presentation of
neoantigens for immune surveillance.
Assessing bias in neoantigen affinities in patients with
mutant HLA alleles
McGranahan et al. reported that in lung cancer, sub-
clones that had lost a particular HLA allele tended to ac-
cumulate mutations with higher affinity for the lost
allele, suggesting that such mutations were no longer
subject to immunoediting [9]. We therefore sought to
assess whether mutations accumulating in tumors with
HLA mutations showed a bias in affinity toward the af-
fected HLA allele. We first evaluated whether the num-
ber of mutant-allele specific mutations in these patients
was higher than the average number of mutations spe-
cific to each of the other alleles (Fig. 4c). We observed
several patients for which the number of mutant-allele
specific mutations was indeed higher (Fig. 4c; red lines).
We note that the current study design differs from the
study by McGranahan et al. in that we do not have
subclone-specific sequencing data, and thus can not de-
termine which mutations occurred in the same cell
population as the mutated HLA allele. We also did not
consider allele-specific deletion events, and thus the as-
sumption that the other 5 HLA alleles are intact may be
incorrect for some patients.
Timing of somatic mutations in MHC-I proteins
To better understand B2M and HLA mutation timelines,
we analyzed the tumor allelic fraction of expressed mu-
tations for all patients. Early clonal mutations are
present in a larger fraction of cancer cells than later sub-
clonal mutations and are, therefore, expected to be
present in a higher fraction of the reads generated from
that site during tumor sequencing. Although this as-
sumption can be complicated by sampling bias and
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genomic instability of tumors, we nonetheless expect
that somatic point mutations with higher read support
will in general have occurred at earlier time points than
those with lower read support. Since each individual’s
tumor is unique, we quantified B2M and HLA mutations
in terms of their allelic fraction percentile relative to
other mutations observed in the same tumor (Fig. 4d).
Interestingly, B2M mutations tended to be present at
higher percentiles than most HLA mutations, suggesting
that B2M mutations might occur earlier in tumor devel-
opment and affect a higher proportion of tumor cells.
Most HLA mutations had low percentiles, suggesting
these were late, subclonal events, while a subset had
high percentiles and likely occurred early during tumor
development in those individuals. This observation
agrees with the previous report by McGranahan et al.
that found HLA loss in lung cancer to be predominantly
subclonal with a few observations of clonal loss noted.
Patients with MSI tended to have HLA mutations with
higher variant allele fraction (VAF) (Fisher’s exact test,
OR = 73.3, p < 8.1e-16). These findings remained even
when we considered only mutations in regions unaffected
by copy number changes which can confound VAF
estimates (Additional file 7: Figure S7). Interestingly, we
A B C
D E F
Fig. 4 Analysis of binding neoantigens to patient HLA alleles. a Empirical cumulative distribution function showing the proportion of expressed
missense and indel mutations labeled as binding neoantigens at different PHBR-I score cutoffs in MSS patients. b Boxplots comparing the fraction
of binding neoantigens in tumors with no B2M or HLA mutation (teal) versus patients with a B2M mutation (yellow) or HLA mutation (purple). A
PHBR-I score cutoff of 2 was used to designate a binding neoantigen for this comparison. c Total number of neoantigens that bind to a patient’s
mutated HLA allele versus the average number of neoantigens across the unmutated HLA alleles across all cancer types for MSS patients. A red
line indicates that there are more neoantigens with binding affinity to the mutated HLA allele than the average across the unmutated HLA
alleles; and a blue line depicts the opposite trend. d Allelic fraction percentile distribution for expressed mutations in MSS patients with B2M and
HLA mutations. We used the Kolmogorov-Smirnov statistic to determine whether the two distributions were significantly different. e Comparison
of the number of expressed neoantigens with binding affinity to the patient-specific mutated allele between the low AF percentile (< 40%) and
the high AF percentile (> 60%) HLA mutated patients. Patients with MSI and with mutations in both B2M and HLA genes were excluded.
f Comparison of the total number of neoantigens that bind to a patient-specific mutated HLA allele versus the average number of neoantigens with
binding affinity to the five unmutated HLA alleles in patients with high allelic fraction percentile HLA mutations
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found that tumors with early HLA mutations had signifi-
cantly higher levels of neoantigens predicted to specifically
bind to the mutated allele than tumors with late HLA mu-
tations (Fig. 4e). When we evaluated the bias in specificity
of neoantigens for the mutated allele in patients with early
HLA loss, we found a significant difference in the number
of binding neoantigens between the mutated HLA allele
and average of unmutated HLA alleles (Fig. 4f). We con-
clude that somatic B2M and HLA mutations are associ-
ated with an overall higher burden of neoantigens,
supporting the notion that these mutations facilitate
tumor immune escape.
Correlation of B2M versus HLA mutation with immune
cell infiltration and cytotoxicity
Effective antigen presentation via MHC-I is associated
with CD8+ T cell driven cytotoxicity. Furthermore, cell
surface MHC-I molecules deliver an inhibitory signal to
natural killer (NK) cells. Thus, changes to cell surface
presentation of neoantigens by MHC-I due to mutations
in B2M and HLA may be reflected in immune cell infil-
tration levels and levels of cytotoxicity. We quantified
immune cell infiltration from tumor RNA sequencing
data using Cibersort [16] and levels of cytotoxicity using
the score proposed by Rooney et al. [17]. While Shukla
et al. previously evaluated immune infiltrates and cyto-
toxicity in the context of somatic HLA mutations, to our
knowledge B2M mutations have not previously been an-
alyzed in this context [6].
CD8+ T cell levels were elevated in tumors with HLA
mutations, both pan-cancer (Fig. 5a) and in several
tumor types (Fig. 5b, Additional file 8: Figure S8A). A
possible explanation is that CD8+ T cells are primed in
secondary lymphoid organs and travel to the tumor
where they accumulate due to the lack of the corre-
sponding MHC-I molecule / peptide complex. NK cell
levels were elevated in tumors with B2M mutations pan-
cancer (Fig. 5c), however the levels were not significantly
different in any given tumor type (Fig. 5d, Additional file 8:
Figure S8B). Loss of B2M resulting in reduced cell surface
MHC-I molecules should reduce the ability of tumor cells
to inhibit NK cell driven cytotoxicity, however it is unclear
whether this would affect NK cell levels in the tumor. Cyto-
toxicity was elevated in both HLA and B2M mutant tumors
pan-cancer (Fig. 5e) and in several tumor types (Fig. 5f,
Additional file 8: Figure S8C). These trends are consistent
with the idea that mutations are a mechanism of escape
from immune surveillance, as previously suggested by
Shukla et al. for HLA mutations [6].
Discussion
Many immunotherapies, such as immune checkpoint in-
hibitors, rely on the integrity of patient’s immune system
to eliminate tumors. Tumors use a variety of strategies
to evade the immune system, raising important questions
about how different mechanisms of immune evasion
could impact response to particular immunotherapies. We
found that somatic point mutations in proteins compris-
ing the MHC-I, B2M and HLA, showed signs of positive
selection in tumors. This observation motivated our study
of the effects of somatic B2M and HLA mutations on ac-
cumulation of putative neoantigens in tumors.
Our analysis builds on work by Shukla et al. that first
applied Polysolver to evaluate patterns of HLA mutation
across tumors and showed that such mutations occurred
preferentially in tumors with high mutation burden and
under strong pressure by the immune system as evi-
denced by high levels of CD8+ T cell infiltration [6].
Here we further analyze patterns of mutation in tumors
with HLA mutations, incorporating information about
which mutations are likely to be presented by MHC-I
molecules derived from patient-specific HLA alleles, and
comparing to tumors with B2M mutations or with un-
altered MHC-I. Our analysis supports a model where
B2M mutations reduce the overall levels of cell surface
MHC-I molecules while HLA mutations perturb the
overall composition of the MHC-I complex landscape,
both providing escape from immune surveillance. Our
findings are consistent with those of McGranahan et al.
who reported that somatic loss of heterozygosity in the
HLA locus was a common mechanism of immune eva-
sion, and that loss of a specific HLA allele could render
a subset of neoantigens within the tumor ineffective at
generating an immune response upon checkpoint in-
hibition [9]. While both B2M and HLA mutated pa-
tients showed elevated mutation rates, we observed
differences in how neoantigens accumulated in these
tumors, with B2M mutant tumors harboring the most
neoantigens and tumors with intact MHC-I molecules
harboring the least.
Notably, B2M mutations were highly enriched in tu-
mors with microsatellite instability, a phenomenon that
has been previously observed in the context of colorectal
cancer [18] and is now confirmed for other tumor types
with high MSI. MSI tumors were associated with higher
immune cell infiltration and robust immune responses
in this disease [19]. Previous studies have also linked
B2M mutations to increased levels of local immune
cytolytic activity in uterine, stomach, colorectal and
breast cancer [17]. It remains unclear to what extent
high mutation burden precedes immune infiltration,
cytotoxicity and escape via B2M or HLA mutation, or
whether the rate and affinity characteristics of the muta-
tions that occur after the event differ from those before.
Grasso et al. [20] showed that MSI-H colorectal tumors
disrupt B2M and HLA genes independent of mutational
load with direct effect on T cell infiltration. We conclude
that mutations to either component of MHC-I will
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Fig. 5 Increased NK, CD8+ T-cell and cytotoxicity levels are associated with mutations in MHC-I. a and c and e Boxplots comparing MSS TCGA
patients with or without B2M or HLA mutations, in terms of their (a) CD8+ T cell levels, (c) natural killer (NK) cell levels, and (e) cytotoxicity scores.
Sample sizes for each patient group are written under their name. b and d and f) Boxplots comparing MSS TCGA patients with or without B2M
or HLA mutations, in terms of their (b) CD8+ T cell levels, (d) natural killer (NK) cell levels, and (f) cytotoxicity scores. Patients are divided by tumor
type and only the tumor types with at least 5 mutated patients are shown. P-values are adjusted for multiple comparisons. Sample sizes for each
patient group are written under the tissue name
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provide effective escape in the setting of a robust anti-
tumor immune response, however mutations to B2M
may be more beneficial in settings such as MSI when
the number of neoantigens generated is highest.
We note that the current analysis has several limita-
tions. First, our analysis only considered mutations in
HLA alleles, whereas other types of variation, including
loss of heterozygosity or lack of expression could confer
similar effects. In the current analysis, patients with such
effects would be grouped with non-mutated tumors,
which would reduce the statistical power of the analyses
that we performed. In addition, we did not have infor-
mation about the subclonal membership of particular
mutations within the tumor, and thus could not distin-
guish mutations occurring in the subset of tumor cells
with HLA mutation from other mutations in the tumor.
Knowledge of the subclonal architecture of the tumor
would be helpful to fully investigate the affinity bias of
new mutations for the mutated HLA allele. Future stud-
ies should address these shortcomings.
Conclusion
Here we show that somatic mutations affecting B2M
and HLA genes interact with the accumulation of som-
atic mutations that generate neoantigens during tumor
development. Mutations in both genes relieve pressure
by the immune system, allowing the tumor to evade an
active immune response. A better understanding of how
these mutations differ in shaping the oncogenic land-
scape may provide insights as to how these factors could
contribute to resistance to therapies that induce strong
local anti-tumor immunity.
Methods
Data
All available whole exome sequencing (WXS) data as of
5/3/2018 was downloaded from The Cancer Genome
Atlas (TCGA) database via their Genomic Data Com-
mons (GDC) client. Both .bam files and auxiliary .bai
files were downloaded. All available somatic mutation
data as of 5/21/2018 was downloaded from the TCGA
database in the form of TCGA project mutation annota-
tion files (MAF). Clinical data were also obtained from
the GDC (downloaded on 4/25/2017) (Additional file 9:
Table S1).
Protein structure analysis
Experimental 3D X-ray protein structures for the B2M
and HLA-A/B/C complexes were obtained from the Pro-
tein Data Bank (PDB) [11]. Amino acid residues of each
PDB structure were annotated based on their 3D loca-
tion in the protein as core and surface according to their
relative solvent accessible surface area (RSA) calculated
using Naccess [21]. Residues with RSA higher than 15
were annotated as surface and residues with RSA lower
than 5 were annotated as core, while residues with RSA
values between 5 and 15 were annotated as ambiguous.
Residues involved in the physical interaction between
B2M and HLA proteins are predicted using KFC2 [22]
and annotated as interface. PDB residue positions were
mapped onto the UniProt residue positions using the
PDBSWS server [23]. UniProt residues are numbered
based on their position in the protein sequence of the
full-length protein, starting from 1. If multiple PDB
structures were available for the same protein, we took
consensus as the final annotation; and in the case of a
tie, the residue was labeled as ambiguous. The residues
without known 3D structure are also labeled as ambigu-
ous. We had structures for 6 alleles of HLA-A protein,
15 alleles of HLA-B protein, and 3 alleles of HLA-C pro-
tein. We took consensus of residue annotations of differ-
ent HLA alleles to annotate each HLA protein. VMD
[24] is used to visualize protein 3D structures (Fig. 2b).
Exon information for HLA proteins is obtained from the
IMGT/HLA database (v3.34; https://www.ebi.ac.uk/ipd/
imgt/hla/) [25].
HLA typing and mutation calling
HLA genotyping and mutation calling was performed
for HLA-A, HLA-B, and HLA-C genes, which encode
the human MHC-I complex. We extracted scripts from
the Broad Institute’s Polysolver Docker container
(https://software.broadinstitute.org/cancer/cga/polysolver_
run). We verified that the majority of Polysolver’s HLA calls
were consistent with that of xHLA [26] (Additional file 10:
Figure S9) and therefore used all available Polysolver re-
sults. B2M mutations were taken directly from the TCGA
MAF files. Patients with somatic B2M or HLA mutations
were grouped for subsequent analysis and compared to pa-
tients that had neither. We found that only 13 patients had
both B2M and HLA mutations (Additional file 9: Table S2).
Microsatellite instability
Microsatellite instability scores for all TCGA patients
were obtained from Kautto et al., 2017. Patient MANTIS
scores from the paper were binarized to microsatellite
instable (MSI-H) and stable (MSS) according to the rec-
ommended MANTIS score threshold of 0.4 [14].
Determining expressed mutations
We used the bam-readcount tool (https://github.com/
genome/bam-readcount) to determine how many RNA-
seq reads covered a mutated position. To count a mu-
tation as being expressed, we used a read count
threshold of 5.
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Determining regions with CNVs
Regions affected by copy number variants were deter-
mined from TCGA affymetrix SNP6 data by using 0.1
thresholds as the cutoff in either direction. Thus, any
region that has a log2 fold change larger than 0.1 or
smaller than − 0.1 is defined as a position with copy num-
ber variation [27]. For the Additional file 7: Figure S7 we
excluded any mutations that occurred in regions with
copy number variation.
Mutation burden
Mutation counts were obtained from TCGA MAF files
for all patients. To obtain nonsynonymous counts, we
filtered out mutations outside of coding regions as well
as silent mutations and tallied the remaining mutations
for each patient. We retained only expressed mutations,
and added a pseudocount of 1 for all patients, for all
mutation burden analyses. For cancer-type-specific ana-
lysis, patients from TCGA tumor types COAD and
READ were merged under the name CRC (colon and
rectal cancer).
Antigen affinity
We used the netMHCpan4.0 tool [15, 28] to obtain mu-
tation affinity scores for all patient HLA alleles. To de-
termine whether a mutation would be effectively bound
as a neoantigen to the MHC-I complex, we binarized af-
finity scores: mutations with scores <= 2 we considered
binding, and mutations with scores > 2 we considered
non-binding [8, 15]. We then took the harmonic mean
of the best ranking neoantigen to calculate the Patient
Harmonic-mean Best Rank (PHBR) score [8]. To evalu-
ate differences in fraction of binding neoantigens at vari-
ous presentation score (PHBR-I score) cutoffs, we
plotted the empirical cumulative distribution function
(ECDF) using the median fraction of neoantigens gener-
ated from expressed mutations across patients. The
Kolmogorov-Smirnov test was used to determine
whether the distribution of neoantigen fractions was sig-
nificantly different for each group (Fig. 4a). To deter-
mine if the number of neoantigens was significantly
different between mutated and control patients at a par-
ticular PHBR-I score threshold, we calculated p-values
using an unpaired Mann Whitney test for pan-cancer
comparisons (Fig. 4b). To test the significance of the
number of neoantigens between mutated and unmutated
HLA alleles, we used a paired Wilcoxon test (4C, 4F).
The Kolmogorov-Smirnov, Mann Whitney, and Wil-
coxon tests implemented in the scipy.stats Python pack-
age were used for these analyses.
Allelic fraction analysis
For Polysolver-determined HLA mutations, we obtained
the tumor allelic fraction (“tumor_f”) from the Mutect
output files generated by Polysolver. For all other muta-
tions we calculated tumor allelic fraction from tumor al-
ternate allele reads (“t_alt_count”) and tumor read depth
(“t_depth”) from TCGA MAF files. B2M and HLA mu-
tations were further annotated according to their per-
centile within the ranked list of mutations in the tumor
where they were observed. To determine if the distribu-
tions of patients with B2M and HLA mutations were
significantly different than patients without these muta-
tions, we used an unpaired Mann Whitney statistical test
from the scipy.stats Python package.
Immune infiltration and cytotoxicity
Immune cell infiltration levels for CD8+ T cells and nat-
ural killer cells were obtained by running Cibersort with
default parameters and without quantile normalization,
on log2 TPM values obtained by reprocessing the TCGA
RNAseq data through Sailfish V0.7.6 [29]. Cytotoxicity
was estimated as described in [17], by summing the z-
scored log2 TPM expression values of granzyme A
(GZMA) and perforin (PRF1). For cancer-type-specific
analysis, patients from TCGA tumor types COAD and
READ were merged under the name CRC (colon and
rectal cancer).
Other statistical considerations
Where appropriate, p-values were adjusted for multiple
comparisons using the Benjamini-hochberg method [30].
Additional files
Additional file 1: Figure S1. MHC-I complex 3D structure. 3D crystal
structure of MHC-I complex is displayed as B2M/HLA-A complex (PDB:
3bo8). Interface (blue and violet) and core (green and orange) regions of
B2M and HLA-A proteins are highlighted, respectively. Transparent blue
and violet regions correspond to the surface regions of B2M and HLA-A
proteins, respectively. (PDF 1324 kb)
Additional file 2: Figure S2. B2M interface residue positions for HLA
alleles. Residues on B2M that interact with HLA-A, HLA-B, HLA-C proteins
are highlighted black. (PDF 381 kb)
Additional file 3: Figure S3. Increased mutation burden associated
with mutations in HLA, related to Fig. 3. (A and B) Boxplots showing total
number of nonsynonymous mutations for (A) MSI and MSS and (B) MSS
only TCGA patients with or without HLA mutations for additional tissue
types not shown in Figs. 3b, or d. Patients are divided by tumor type.
Only the tumor types containing at least 5 mutated patients and that
have not been reported in Fig. 3 are shown. P-values are adjusted for multiple
comparisons using the Benjamini–Hochberg procedure. (PDF 435 kb)
Additional file 4: Figure S4. Tumor stage analysis for patients with B2M
and HLA mutations. Percentage distribution of tumor stages for the
patients with or without B2M and HLA mutations. (PDF 343 kb)
Additional file 5: Figure S5. Mutation burden in CCLE, related to Fig. 3.
Boxplots showing the total number of nonsynonymous mutations for
CCLE cell lines who acquired a B2M or HLA versus cell lines that did not
acquire any B2M or HLA mutation. Sample sizes for each group are written
under their name. (PDF 345 kb)
Additional file 6: Figure S6. Total number of binding neoantigens to
patient HLA alleles, related to Fig. 4. (A) Distribution of median total
counts of binding neoantigens at different PHBR-I score cutoffs for MSS
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patients. (B) Boxplots comparing the number of neoantigens in MSS
patients with no B2M or HLA mutation (teal) versus MSS patients with a
B2M mutation (yellow) or an HLA mutation (purple). A PHBR-I score cutoff
of 2 was used to designate a binding neoantigen for this comparison.
(PDF 419 kb)
Additional file 7: Figure S7. Allelic fraction percentile distribution for
patients with B2M and HLA mutations accounting for aneuploidy, related
to Fig. 4. Allelic fraction percentile distribution for expressed mutations in
MSS patients with B2M and HLA mutations, excluding all mutations
occurring in regions affected by CNVs. Patients that have both B2M
and HLA mutations are excluded. (PDF 330 kb)
Additional file 8: Figure S8. NK, CD8+ T-cell and cytotoxicity levels of
patients with mutations in HLA, related to Fig. 5. (A-B-C) Boxplots
comparing MSS TCGA patients with or without HLA mutations for
additional tissue types not shown in Fig. 5(B-D-F), in terms of their
(A) CD8+ T-cell levels, (B) NK cell levels, and (C) cytotoxicity scores.
Patients are divided by tumor type and only the tumor types with at
least 5 mutated patients and that have not been reported in Fig. 5
are shown. P-values are adjusted for multiple comparisons using the
Benjamini–Hochberg procedure. (PDF 428 kb)
Additional file 9: Table S1. Summary of data availability for specific
analyses. List of TCGA patients analyzed in the manuscript, annotated
according to data availability for inclusion in specific analyses. Table S2.
List of patients with B2M or HLA mutations. Duplicate patient mutation
rows indicate that both HLA alleles are mutated. (XLSX 331 kb)
Additional file 10: Figure S9. HLA allele call comparison between
Polysolver and xHLA. Barplot showing matched Polysolver HLA calls
and calls with major and minor subtype differences. (PDF 337 kb)
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